Are tricyclic antidepressants effective medicine or just a placebo effect in disguise?

Nature · Published 3 October 2026 Swipe more like this →

In short: Discovered in the 1950s, tricyclic antidepressants were once the gold standard for treating depression. Named for their three-ringed chemical structure, these drugs work by inhibiting neurotransmitter reuptake. Yet, recent meta-analyses suggest their actual clinical benefit remains surprisingly difficult to distinguish from the placebo effect, raising questions about their true efficacy.

Tricyclic antidepressants (TCAs) were first identified in the 1950s, with psychiatrist Roland Kuhn famously investigating imipramine as a potential antipsychotic. While it failed to treat schizophrenia, its mood-altering properties were quickly recognized. These agents function by inhibiting the reuptake of norepinephrine, serotonin, and dopamine, allowing these neurotransmitters to accumulate in the brain. For decades, they served as the primary pharmacological treatment for major depressive disorder.

Despite their history, TCAs have largely been supplanted in modern clinical practice by newer classes like selective serotonin reuptake inhibitors (SSRIs). This shift is primarily due to the safety profile of newer drugs; TCAs are associated with significant side effects, including dry mouth, blurred vision, constipation, and cardiac toxicity. Because the therapeutic benefits often take two to four weeks to emerge—while side effects appear almost immediately—patients may struggle with adherence. Furthermore, the risk of lethal overdose is higher with TCAs compared to newer alternatives.

The scientific consensus on their efficacy is currently under scrutiny. A 2024 systematic review and meta-analysis of 103 short-term clinical trials involving 10,590 participants found only a small benefit over placebo. Crucially, researchers noted that because side effects can reveal whether a patient is receiving the active drug or a placebo, the study results might be skewed by unblinding. This makes it difficult to determine if the observed improvements are genuine pharmacological effects or amplified placebo responses. Given the low quality of evidence and high risk of bias, the true clinical value of these drugs remains a subject of intense debate.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• How a failed antipsychotic became the world's first tricyclic antidepressant
• The complex reality of how antidepressants actually function
• Are you confusing antidepressants with depressants? They are fundamentally different chemical tools.
• America's favourite psychiatric drug works about as well as its rivals
• An antidepressant became a go-to sleep drug despite a guideline against it
• Compact forest jewels whose order is still a phylogenetic puzzle
• Three-horned giants of Laramidia’s last Cretaceous days
• Tromsø: An Arctic Frontier City Where the Sun Disappears for Nearly Two Months
• Why these tiny, primate-like mammals are the ultimate evolutionary outliers of the forest
• The Canadian rock band that became a national cultural institution
• How a 2009 blockbuster reimagined ancient cosmic history through the lens of alien machinery.
• Linnaeus saw Roman battle trophies in the humble garden nasturtium

More in Organisms · More in Nature · Latest · A–Z · All topics